Key result
MMP inhibition with PD166793 attenuates post-MI remodeling, reducing left ventricular end-diastolic dimension.
Why the study?
Activation of matrix metalloproteinases is a potential mechanism for LV remodeling after MI, but the effects of MMP inhibition on regional LV geometry and MMP levels after MI require investigation.
RCT (n=31)
randomized
Absolute Event Rate: 4.7% vs 5.1%
p-value: p=<0.05
No takes yet. Share an insight, caveat, or question.
MMP inhibition may limit post-MI remodeling; hypothesis-generating and requires confirmation in randomized trials before practice change.
Michael R. Zile (2003) conducted an RCT in Myocardial Infarction (n=31). PD166793 (Matrix metalloproteinase inhibitor) vs. MI only was evaluated on Left ventricular end-diastolic dimension at 8 weeks (p=<0.05). Matrix metalloproteinase inhibition with PD166793 significantly reduced left ventricular end-diastolic dimension and attenuated regional infarct expansion compared to control at 8 weeks post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: